|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
® and Changed as of 6/29/20 by the SEC on 7/7/20.As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 6/29/20 Actinium Pharmaceuticals, Inc. 10-Q® 3/31/20 40:2.1M Edgar Agents LLC/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 366K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 18K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 18K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 14K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 14K
12: R1 Document and Entity Information HTML 47K
13: R2 Consolidated Balance Sheets (Unaudited) HTML 85K
14: R3 Consolidated Balance Sheets (Unaudited) HTML 36K
(Parenthetical)
15: R4 Consolidated Statements of Operations (Unaudited) HTML 44K
16: R5 Consolidated Statement of Changes in Stockholders' HTML 46K
Equity (Unaudited)
17: R6 Consolidated Statements of Cash Flows (Unaudited) HTML 71K
18: R7 Description of Business and Summary of Significant HTML 48K
Accounting Policies
19: R8 Commitments and Contingencies HTML 23K
20: R9 Leases HTML 39K
21: R10 Equity HTML 41K
22: R11 Description of Business and Summary of Significant HTML 79K
Accounting Policies (Policies)
23: R12 Description of Business and Summary of Significant HTML 24K
Accounting Policies (Tables)
24: R13 Leases (Tables) HTML 38K
25: R14 Equity (Tables) HTML 31K
26: R15 Description of Business and Summary of Significant HTML 27K
Accounting Policies (Details)
27: R16 Description of Business and Summary of Significant HTML 22K
Accounting Policies (Details 1)
28: R17 Description of Business and Summary of Significant HTML 15K
Accounting Policies (Details Textual)
29: R18 Commitments and Contingencies (Details 1) HTML 32K
30: R19 Leases (Details) HTML 26K
31: R20 Leases (Details 1) HTML 29K
32: R21 Leases (Details 2) HTML 19K
33: R22 Leases (Details 3) HTML 18K
34: R23 Leases (Details 4) HTML 29K
35: R24 Leases (Details Textual) HTML 15K
36: R25 Equity (Details) HTML 67K
37: R26 Equity (Details Textual) HTML 72K
39: XML IDEA XML File -- Filing Summary XML 65K
38: EXCEL IDEA Workbook of Financial Reports XLSX 40K
6: EX-101.INS XBRL Instance -- atnm-20200331 XML 406K
8: EX-101.CAL XBRL Calculations -- atnm-20200331_cal XML 92K
9: EX-101.DEF XBRL Definitions -- atnm-20200331_def XML 216K
10: EX-101.LAB XBRL Labels -- atnm-20200331_lab XML 539K
11: EX-101.PRE XBRL Presentations -- atnm-20200331_pre XML 372K
7: EX-101.SCH XBRL Schema -- atnm-20200331 XSD 99K
40: ZIP XBRL Zipped Folder -- 0001213900-20-016168-xbrl Zip 64K
Exhibit 31.2
CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
I, Steve O’Loughlin, certify that:
1. I have reviewed this Form 10-Q of Actinium Pharmaceuticals, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods present in this report;
4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financing reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involved management or other employees who have a significant role in the registrant’s internal control over financial reporting.
| Date: June 29, 2020 | ||
| By: | /s/ Steve O’Loughlin | |
| Steve O’Loughlin | ||
| Principal Financial Officer | ||
| (Duly Authorized Officer and Principal Financial and Accounting Officer) | ||
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Corrected on: | 7/7/20 | None on these Dates | ||
| Filed on / Changed on: | 6/29/20 | |||
| For Period end: | 3/31/20 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/07/20 Actinium Pharmaceuticals, Inc. S-3 4:702K EdgarAgents LLC/FA |